Table 1 Baseline characteristics of all patients
|  | Ulinastatin group (n = 142) | Tranexamic acid group (n = 143) | Placebo group (n = 141) | p |
|---|---|---|---|---|
Baseline demographics | ||||
 Male n,(%) | 63 (44.37%) | 66 (46.15%) | 71 (50.35%) | 0.585 |
 Age (yrs) | 49.0 ± 14.3 | 48.6 ± 12.7 | 50.3 ± 12.4 | 0.562 |
 Weight (kg) | 61.7 ± 11.7 | 61.4 ± 12.0 | 61.4 ± 12.7 | 0.907 |
 Body mass index | 23.1 ± 3.6 | 22.9 ± 3.4 | 22.8 ± 3.7 | 0.686 |
Diagnosis | 0.631 | |||
 Coronary heart disease, n(%) | 17 (11.97%) | 13 (9.09%) | 21 (14.89%) |  |
Valvular heart disease, n(%) | ||||
 Mitral valve lesion, n(%) | 70 (49.30%) | 66 (46.15%) | 63 (44.68%) |  |
 Aortic valve lesion, n(%) | 24 (16.90%) | 23 (16.08%) | 19 (13.48%) |  |
 Combined lesion, n(%) | 21 (14.79%) | 19 (13.29%) | 19 (13.48%) |  |
Congenital heart disease, n(%) | ||||
 Atrial septal defect, n(%) | 1 (0.70%) | 4 (2.80%) | 6 (4.26%) |  |
 Ventricular septal defect, n(%) | 4 (2.82%) | 6 (4.20%) | 5 (3.55%) |  |
 Other, n(%) | 5 (3.52%) | 12 (8.39%) | 8 (5.67%) |  |
Clinical history (%) | ||||
 Hypertension | 31 (21.83%) | 33 (23.08%0 | 37 (26.24%) | 0.668 |
 Diabetes | 5 (3.52%) | 4 (2.80%) | 6 (4.26%) | 0.801 |
 Stroke | 7 (4.93%) | 3 (2.10%) | 2 (1.42%) | 0.166 |
 Chronic pulmonary disease | 10 (7.04%) | 19 (13.29%) | 15 (10.64%) | 0.221 |
 Liver dysfunction | 0 (0%) | 0 (0%) | 0 (0%) | – |
 Renal dysfunction | 0 (0%) | 1 (0.70%) | 2 (1.42%) | 0.361 |
NYHA class (%) | 0.610 | |||
 I | 10 (7.04%) | 18 (12.59%) | 18 (12.77%) |  |
 II | 81 (57.04%) | 75 (52.45%) | 78 (55.32%) |  |
 III | 41 (28.87%) | 36 (25.17%) | 35 (24.82%) |  |
 IV | 10 (7.04%) | 14 (9.79%) | 10 (7.09%) |  |
 Euroscore II | 2.41 ± 1.87 | 2.63 ± 1.73 | 2.50 ± 1.75 | 0.549 |